Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 positive breast carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT03617341
What this trial is testing

Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer With HER2 PositiveTriple Negative Breast Cancer
Yonsei University 200
Large-scale testing (Phase 3)Study completedNCT01547741
What this trial is testing

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
NSABP Foundation Inc 4,242
Testing effectiveness (Phase 2)UnknownNCT04247633
What this trial is testing

High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

Who this might be right for
Breast Cancer
Samsung Medical Center 578
Large-scale testing (Phase 3)Active Not RecruitingNCT06016738
What this trial is testing

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 510
Early research (Phase 1)Active Not RecruitingNCT07557004
What this trial is testing

SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Who this might be right for
HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT07732491
What this trial is testing

Culmerciclib in HR+/HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastastic Breast CancerHER2+ Advanced Breast Cancer
Sun Yat-sen University 35
Testing effectiveness (Phase 2)UnknownNCT05154396
What this trial is testing

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Chinese Academy of Medical Sciences 60
Not applicableStudy completedNCT05945927
What this trial is testing

Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 178
Testing effectiveness (Phase 2)Looking for participantsNCT07299825
What this trial is testing

A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Who this might be right for
Her 2 Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 40
Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Testing effectiveness (Phase 2)Study completedNCT02048059
What this trial is testing

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Who this might be right for
Breast CancerBrain Metastases
Angiochem Inc 72
Testing effectiveness (Phase 2)UnknownNCT05042791
What this trial is testing

Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Who this might be right for
HER2-positive Metastatic Breast Cancer
Jiangxi Provincial Cancer Hospital 362
Testing effectiveness (Phase 2)Study completedNCT00134680
What this trial is testing

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

Who this might be right for
Metastatic Breast Cancer
Duke University 33
Not applicableUnknownNCT02101879
What this trial is testing

Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes

Who this might be right for
Cardiotoxicity.Anti Her2 Therapy.Metastatic Breast Cancer
Rambam Health Care Campus 20
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Not applicableLooking for participantsNCT06856200
What this trial is testing

Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Who this might be right for
Advanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy
Fudan University 36
Large-scale testing (Phase 3)Study completedNCT01810393
What this trial is testing

Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

Who this might be right for
Breast Cancer
Hoffmann-La Roche 114
Large-scale testing (Phase 3)UnknownNCT00430001
What this trial is testing

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Danish Breast Cancer Cooperative Group 300
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Active Not RecruitingNCT04293393
What this trial is testing

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Spanish Breast Cancer Research Group 200
Next Page